Can Resveratrol Influence the Activity of 11β-Hydroxysteroid Dehydrogenase Type 1? A Combined In Silico and In Vivo Study

被引:6
|
作者
Novak, Jurica [1 ,2 ]
Tseilikman, Vadim E. [3 ]
Tseilikman, Olga B. [3 ,4 ]
Lazuko, Svetlana S. [5 ]
Belyeva, Lyudmila E. [6 ]
Rahmani, Azam [7 ]
Fedotova, Julia [8 ]
机构
[1] Univ Rijeka, Dept Biotechnol, Rijeka 51000, Croatia
[2] Univ Rijeka, Ctr Artificial Intelligence & Cyber Secur, Rijeka 51000, Croatia
[3] South Ural State Univ, Sci & Educ Ctr Biomed Technol, Sch Med Biol, Chelyabinsk 454080, Russia
[4] Chelyabinsk State Univ, Fac Fundamental Med, Chelyabinsk 454001, Russia
[5] Vitebsk State Med Univ, Dept Physiol, Frunze Av 27, Vitebsk 210023, BELARUS
[6] Vitebsk State Med Univ, Dept Pathophysiol, Frunze Av 27, Vitebsk 210023, BELARUS
[7] Univ Tehran Med Sci, Nursing & Midwifery Care Res Ctr, Sch Nursing & Midwifery, POB 14665-354, Tehran, Iran
[8] IP Pavlov Inst Physiol RAS, Lab Neuroendocrinol, 6 Emb Makarova, St Petersburg 199034, Russia
关键词
11 beta-hydroxysteroid dehydrogenase type 1; resveratrol; PTSD; corticosterone; molecular dynamics; plus maze test; STRESS; BRAIN; MODEL;
D O I
10.3390/ph16020251
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD-1) is an NADPH-dependent reductase, responsible for the activation of cortisol by reducing cortisone. Resveratrol (RES), a type of natural polyphenol, is reported to be able to slow the progression of cancer and cardiovascular disease and improve the health of mice on a high-calorie diet. In this article, we applied molecular docking and molecular dynamics simulations to investigate the possibility of binding RES to 11 beta-HSD-1. The 11 beta-HSD-1:RES complex is stable on the mu s time scale, and backbone RMSD-based clustering identified three conformations. Special attention was paid to the interaction pattern between the ligand and the target molecule, revealing hydrogen bonds between the hydroxyl group of RES and Thr124, as well as hydrophobic interactions responsible for the binding. In vivo studies demonstrated the ability of resveratrol at a dose of 40 mg/kg to reduce 11 beta-HSD-1 activity in the liver of rats under conditions of experimental post-traumatic stress disorder (PTSD), as well as in non-stressed animals. In both cases, the resveratrol-induced reduction in 11 beta-HSD-1 activity was accompanied by an increase in plasma corticosterone levels and a decrease in anxiety levels in the plus maze test.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus
    Valsamakis, G
    Anwar, A
    Tomlinson, JW
    Shackleton, CHL
    McTernan, PG
    Chetty, R
    Wood, PJ
    Banerjee, AK
    Holder, G
    Barnett, AH
    Stewart, PM
    Kumar, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (09): : 4755 - 4761
  • [42] Glucocorticoids, 11β-hydroxysteroid dehydrogenase type 1, and visceral obesity
    Paulmyer-Lacroix, O
    Boullu-Ciocca, S
    Oliver, C
    Dutour, A
    Grino, M
    M S-MEDECINE SCIENCES, 2003, 19 (04): : 473 - 476
  • [43] Perhydroquinolylbenzamides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1
    Coppola, GM
    Kukkola, PJ
    Stanton, JL
    Neubert, AD
    Marcopulos, N
    Bilci, NA
    Wang, H
    Tomaselli, HC
    Tan, J
    Aicher, TD
    Knorr, DC
    Jeng, AY
    Dardik, B
    Chatelain, RE
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (21) : 6696 - 6712
  • [44] Oxazolones as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1
    Sutin, Lori
    Andersson, Soeren
    Bergquist, Lars
    Castro, Victor M.
    Danielsson, Eva
    James, Stephen
    Henriksson, Martin
    Johansson, Lars
    Kaiser, Christina
    Flyren, Katarina
    Williams, Meredith
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (17) : 4837 - 4840
  • [45] 11β-hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents
    Webster, Scott Peter
    Pallin, Thomas David
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (12) : 1407 - 1422
  • [46] Small Molecule 11β- Hydroxysteroid Dehydrogenase Type 1 Inhibitors
    Sun, Daqing
    Wang, Minghan
    Wang, Zhulun
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (12) : 1464 - 1475
  • [47] Cortisol, 11β-hydroxysteroid dehydrogenase type 1 and central obesity
    Stewart, PM
    Tomlinson, JW
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (03): : 94 - 96
  • [48] 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome
    Schnackenberg, Christine G.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (03) : 295 - 300
  • [49] 11 beta-Hydroxysteroid dehydrogenase type 1 and bone
    Cooper, M. S.
    OSTEOLOGIE, 2016, 25 (04) : 256 - 261
  • [50] Type 2 11β-hydroxysteroid dehydrogenase activity in human ovarian cancer
    Temkin, Sarah
    Nacharaju, Vijaya L.
    Hellman, Mira
    Lee, Yi-Chun
    Abulafia, Ovadia
    STEROIDS, 2006, 71 (11-12) : 1019 - 1023